The FluoTag-Q anti-SARS-CoV-2 S1 is based on the W25 clone, which has a sub-nanomolar affinity for the SARS-CoV-2 S1 protein receptor binding domain (RBD) and can neutralize infections as it efficiently competes with ACE-2 receptor binding.
This anti-Sars-CoV-2 Spike protein S1 nanobody was developed by the team of Alejandro Rojas-Fernandez at the Institute of Medicine at the Universidad Austral de Chile. We acquired the exclusive license to produce this nanobody and make it available for research and development purposes. The FluoTag-Q anti-SARS-CoV-2 S1 is based on the W25 clone, which has a sub-nanomolar affinity for the SARS-CoV-2 S1 protein receptor binding domain (RBD) and can neutralize infections as it efficiently competes with ACE-2 receptor binding.
For detailed information regarding our FluoTag-Q, -X2 and -X4 series check our technology section here.
|Specificity:||Recognizes the RBD of the SARS-CoV-2 S1 protein.|
|Formulation:||Lyophilized from PBS pH 7.4. Reconstitute with 200 µL 50 % glycerol including 0.1 % sodium azid as preservative if applicable.|
|Storing:||Vials containing lyophilized protein can be stored at 4 °C for 6 months. We recommend reconstituting the protein with 50 % sterile glycerol including 0.1 % sodium azide as preservative if applicable. Minimize the number of freeze-thaw cycles by aliquoting the reconstituted protein. Long term storage at -80 °C for up to 6 months. Working aliquots can be stored at -20 °C for up to 4 weeks. We do not recommend storing the reconstituted protein at 4 °C.|
Potent neutralization of clinical isolates of SARS-CoV-2 D614 and G614 variants by a monomeric, sub-nanomolar affinity Nanobody
|Notice:||To be used in vitro/ for research only. Non-toxic, non-hazardous, non-infectious.|
|Legal terms:||By purchasing this product you agree to our general terms and conditions.|